Coene Karlien L M, Timmer Corrie, Goorden Susan M I, Ten Hoedt Amber E, Kluijtmans Leo A J, Janssen Mirian C H, Rennings Alexander J M, Prinsen Hubertus C M T, Wamelink Mirjam M C, Ruijter George J G, Körver-Keularts Irene M L W, Heiner-Fokkema M Rebecca, van Spronsen Francjan J, Hollak Carla E, Vaz Frédéric M, Bosch Annet M, Huigen Marleen C D G
Translational Metabolic Laboratory, Department of Laboratory Medicine Radboud University Medical Centre Nijmegen The Netherlands.
Department Endocrinology and Metabolism Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands.
JIMD Rep. 2020 Nov 22;58(1):70-79. doi: 10.1002/jmd2.12186. eCollection 2021 Mar.
Reliable measurement of phenylalanine (Phe) is a prerequisite for adequate follow-up of phenylketonuria (PKU) patients. However, previous studies have raised concerns on the intercomparability of plasma and dried blood spot (DBS) Phe results. In this study, we made an inventory of differences in (pre-)analytical methodology used for Phe determination across Dutch laboratories, and compared DBS and plasma results.
Through an online questionnaire, we assessed (pre-)analytical Phe measurement procedures of seven Dutch metabolic laboratories. To investigate the difference between plasma and DBS Phe, participating laboratories received simultaneously collected plasma-DBS sets from 23 PKU patients. In parallel, 40 sample sets of DBS spotted from either venous blood or capillary fingerprick were analyzed.
Our data show that there is no consistency on standard operating procedures for Phe measurement. The association of DBS to plasma Phe concentration exhibits substantial inter-laboratory variation, ranging from a mean difference of -15.5% to +30.6% between plasma and DBS Phe concentrations. In addition, we found a mean difference of +5.8% in Phe concentration between capillary DBS and DBS prepared from venous blood.
The results of our study point to substantial (pre-)analytical variation in Phe measurements, implicating that bloodspot Phe results should be interpreted with caution, especially when no correction factor is applied. To minimize variation, we advocate pre-analytical standardization and analytical harmonization of Phe measurements, including consensus on application of a correction factor to adjust DBS Phe to plasma concentrations.
可靠地测量苯丙氨酸(Phe)是对苯丙酮尿症(PKU)患者进行充分随访的前提条件。然而,先前的研究对血浆和干血斑(DBS)中Phe检测结果的可比性提出了担忧。在本研究中,我们梳理了荷兰各实验室用于测定Phe的(预)分析方法的差异,并比较了DBS和血浆检测结果。
通过在线问卷,我们评估了荷兰七家代谢实验室的(预)分析Phe测量程序。为了研究血浆和DBS中Phe的差异,参与研究的实验室同时收到了来自23名PKU患者的血浆-DBS样本组。同时,对40组由静脉血或手指毛细血管血制成的DBS样本进行了分析。
我们的数据表明,Phe测量的标准操作程序并不一致。DBS与血浆Phe浓度之间的关联在不同实验室之间存在很大差异,血浆和DBS中Phe浓度的平均差异在-15.5%至+30.6%之间。此外,我们发现毛细血管DBS与静脉血制成的DBS之间的Phe浓度平均差异为+5.8%。
我们的研究结果表明,Phe测量在(预)分析方面存在很大差异,这意味着对血斑Phe检测结果的解读应谨慎,尤其是在未应用校正因子时。为了尽量减少差异,我们提倡对Phe测量进行预分析标准化和分析协调,包括就应用校正因子将DBS中的Phe调整为血浆浓度达成共识。